In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and
Artificial intelligence tools based on large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, suggesting there is some way to go bef
Back in the picturesque West End of London, even a sudden, torrential downpour could not dampen the spirits on 12th March as speakers and attendees returned once more to the Hilton Hotel in
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
